Dr. Reddy’s Laboratories Receives USFDA Observations After Recent Inspection

Dr Reddy’s Laboratories ( (RDY) ) has provided an announcement.

On May 24, 2025, Dr. Reddy’s Laboratories announced that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) inspection at its API manufacturing facility in Miryalaguda, Telangana, India. The inspection, conducted from May 19 to May 24, 2025, resulted in the issuance of a Form 483 with two observations, which the company plans to address within the stipulated timeline. This development is significant as it impacts the company’s compliance status and could influence its market operations and stakeholder confidence.

The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India. It is engaged in the production of a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and generic medications. The company operates in a global market, focusing on providing affordable and innovative medicines.

Average Trading Volume: 2,093,843

Technical Sentiment Signal: Buy

Current Market Cap: $12.06B

Learn more about RDY stock on TipRanks’ Stock Analysis page.